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Summary
The modification of lipid A with 4-amino-4-deoxy-L-
arabinose (Ara4N) allows gram-negative bacteria to
resist the antimicrobial activity of cationic antimicro-
bial peptides and antibiotics such as polymyxin. ArnA
is the first enzyme specific to the lipid A-Ara4N path-
way. It contains two functionally and physically sepa-
rable domains: a dehydrogenase domain (ArnA_DH)
catalyzing the NAD+-dependent oxidative decarboxyl-
ation of UDP-Glucuronic acid (UDP-GlcA), and a
transformylase domain that formylates UDP-Ara4N.
Here, we describe the crystal structure of the full-
length bifunctional ArnA with UDP-GlcA and ATP
bound to the dehydrogenase domain. Binding of
UDP-GlcA triggers a 17 Å conformational change in
ArnA_DH that opens the NAD+ binding site while trap-
ping UDP-GlcA. We propose an ordered mechanism
of substrate binding and product release. Mutation of
residues R619 and S433 demonstrates their importance
in catalysis and suggests that R619 functions as a
general acid in catalysis. The proposed mechanism
for ArnA_DH has important implications for the de-
sign of selective inhibitors.
Introduction
The main component of the outer membrane of gram-
negative bacteria is lipopolysaccharide (LPS). Lipid A
is the conserved, bioactive element of LPS and is com-
monly used as a recognition element for host immune
response to infection. As a means of evading the host
immune system, bacteria have evolved mechanisms to
modify LPS structure in response to environmental
stimuli (Gunn, 2001; Gunn et al., 2000a; Guo et al., 1997).
One such modification is the addition of 4-amino-4-
deoxy-L-arabinose (Ara4N) to phosphate groups in lipid
A. This modification can be triggered in E. coli and Sal-
monella typhimurium by growth in the presence of van-
adate or low concentrations of magnesium (Gunn,
2001; Gunn and Miller, 1996; Gunn et al., 2000b; Guo
et al., 1997). The modification of lipid A with Ara4N is
responsible for bacterial resistance to the action of cat-
ionic antimicrobial peptides (CAMPs) of the innate im-*Correspondence: marcelo.sousa@colorado.edumune system and antibiotics like polymyxin (Roland et
al., 1993, 1994; Shafer et al., 1984).
CAMPs are small, amphipathic, cationic peptides that
interact with the negative charges of the phosphate
groups in LPS (Hoffmann et al., 1999; Scott and Han-
cock, 2000; Zasloff, 2002). These peptides exert their
bactericidal action by permeabilizing the bacterial mem-
brane (Matsuzaki, 1999; Shai, 1999; Yang et al., 2000).
The addition of Ara4N to a phosphate group in lipid A
neutralizes a negative charge on the phosphate and
adds a sugar with a positively charged primary amine.
This results in a lowered affinity of CAMPs for the modi-
fied bacterial membrane that is thought to mediate the
resistance mechanism (Peschel, 2002). The modifica-
tion of lipid A with Ara4N may be responsible, at least
in part, for the persistent infections with Pseudomonas
aeruginosa observed in cystic fibrosis (CF) patients
(Peschel, 2002). Membranes of P. aeruginosa isolated
from CF patients were shown to have the Ara4N modifi-
cation (Ernst et al., 1999).
The enzymes responsible for the synthesis of Ara4N
precursors and its transfer to lipid A are encoded in
the pmrHFIJKLM operon and the pmrE gene (pmr =
Polymyxin resistance) (Gunn et al., 1998). These pro-
teins are highly conserved in gram-negative bacteria
such as E. coli and the human pathogens Pseudomo-
nas aeruginosa, Burkolderia cepacia, Yersinia pestis,
and all types of Salmonella (Breazeale et al., 2005).
Nonpolar mutations of the individual proteins in the op-
eron showed that all proteins, except pmrM, are essen-
tial for the addition of Ara4N to lipid A and polymyxin
resistance (Gunn et al., 2000b), making them excellent
potential targets for drug design. Based on sequence
similarity to known enzymes, a pathway leading to the
synthesis of lipid A-Ara4N has been proposed (Figure
1) (Baker et al., 1999; Breazeale et al., 2002, 2003, 2005;
Zhou et al., 1999). Conversion of UDP-Glucose into
UDP-Glucuronic acid (UDP-GlcA) is catalyzed by the
product of the pmrE gene, a well-characterized dehy-
drogenase (Campbell et al., 2000; Ge et al., 2004; Pero-
zich et al., 1995; Roman et al., 2003; Schiller et al.,
1976). ArnA, the first pathway-specific enzyme, is a
bifunctional protein whose C-terminal domain cata-
lyzes the NAD+-dependent oxidative decarboxyla-
tion of UDP-GlcA to UDP-β-(L-threopentapyranosyl-4$-
ulose) (UDP-4-keto-pentose) (Gatzeva-Topalova et al.,
2004). The transamination of this intermediate to yield
UDP-β-(4-deoxy-4-amino-arabinoase) (UDP-Ara4N) is
catalyzed by ArnB in a reaction with a Keq of w0.1, a
value not favoring transamination (Breazeale et al.,
2003; Noland et al., 2002). The N10-formyltetrahydro-
folate-dependent formylation of UDP-Ara4N to produce
UDP-β-(4-deoxy-4-formamido-L-arabinose) (UDP-Ara4FN)
is catalyzed by the N-terminal domain of the bifunc-
tional ArnA (Breazeale et al., 2005; Gatzeva-Topalova et
al., 2005). However, no formylated sugars are observed
attached to lipid A. The formylation is thus thought to
be a transient step required to compensate for the un-
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930Figure 1. Proposed Biosynthetic Pathway for the Addition of 4-Amino-Arabinose to Lipid A
This figure has been adapted from Breazeale et al., 2005.The pathway starts with UDP-Glucose being oxidized by UDP-Glucose dehydroge-
nase (Ugd) to form UDP-Glucuronic acid (UDP-GlcA). ArnA, the first pathway-specific enzyme, catalyzes the NAD+-dependent oxidation of
UDP-GlcA to UDP-4-keto-pentose with its C-terminal domain. The next enzyme in the pathway, ArnB, catalyzes the transamination reaction,
leading to the formation of UDP-β-(4-deoxy-4-amino-L-arabinose) (UDP-Ara4N). This product is then transiently formylated by the N-terminal
domain of ArnA to produce UDP-β-(4-deoxy-4-formamido-L-arabinose) (UDP-Ara4-Formyl-N). The formylated species is transferred to a
membrane bound undecaprenyl phosphate by ArnC. Additional enzymes in the pathway, which have not yet been fully characterized, com-
plete the pathway, deformylating undecaprenyl-Ara4-FN and transferring Ara4N to lipid A.favorable equilibrium of the transamination reaction H
l(Breazeale et al., 2005). The formylated intermediate is
then transferred to a membrane bound undecaprenyl- d
zphosphate carrier by ArnC (Breazeale et al., 2005).
Raetz and coworkers have recently shown that the r
CArnC transferase is specific for UDP-Ara4FN in vitro
(Breazeale et al., 2005). Additional enzymes in the o
tpmrHFIJKLM operon have been proposed to defor-
mylate undecaprenyl-P-Ara4FN and complete the trans- s
cfer of Ara4N to lipid A. However, their activity has not
yet been demonstrated in vitro (Breazeale et al., 2005; N
cGatzeva-Topalova et al., 2005).
Both the transformylase and dehydrogenase activi- b
ities catalyzed by ArnA are required for lipid A modifica-
tion with Ara4N and polymyxin resistance (Breazeale et G
al., 2005). These activities can be physically separated
by expressing the individual ArnA domains (Breazeale o
aet al., 2005; Gatzeva-Topalova et al., 2004, 2005). The
N-terminal 300 amino acids encode the transformylase d
Nactivity, whereas the C-terminal 360 amino acids are
responsible for the dehydrogenase activity (we pre- t
sviously referred to this domain as ArnA decarboxylase
but hereby adopt the more standard name of ArnA s
bdehydrogenase used by Raetz [Breazeale et al., 2005;
Gatzeva-Topalova et al., 2004]). We have recently solved d
mthe crystal structures of each separate domain in the
absence of ligands (Gatzeva-Topalova et al., 2004, 2005). t
AThe ArnA transformylase domain (ArnA_TF) showed
similarity to other N10-formyltetrahydrofolate binding
enzymes such as glycinamide ribonucleotide formyl- R
transferase (GARF), methionyl-tRNA formyltransferase
(FMT), and the N-terminal hydrolase domain of N10-for- A
amyl-tetrahydrofolate dehydrogenase (Nt-FDH). Muta-
genesis data showed that ArnA_TF utilizes a GARF-like T
mmechanism of formyl transfer relying on residues N ,102104, and D140 to catalyze the reaction (Gatzeva-Topa-
ova et al., 2005). The ligand-free structure of the ArnA
ehydrogenase domain (ArnA_DH) confirmed the en-
yme as a member of the short-chain dehydrogenase/
eductase (SDR) family (Gatzeva-Topalova et al., 2004).
omparison with other SDR enzymes allowed modeling
f substrate binding to ArnA_DH and suggested that
he NAD+ binding site was closed in the ligand-free
tructure. We thus proposed that a conformational
hange triggered by UDP-GlcA binding would open the
AD+ binding site. A role for residues S433 and R619 in
atalysis was also suggested based on the substrate
inding model and the conservation of these residues
n ArnA_DH and other SDR enzymes catalyzing UDP-
lcA decarboxylation (Gatzeva-Topalova et al., 2004).
In this study, we have determined the first structure
f full-length ArnA with the natural substrate UDP-GlcA
nd the NAD+ analog ATP bound to the dehydrogenase
omain. A 17 Å conformational change that opens the
AD+ binding site is observed, as predicted from
he ligand-free ArnA_DH structure. Unexpectedly, this
tructural transition also traps UDP-GlcA in its binding
ite. We propose an ordered mechanism of substrate
inding and product release and probe the roles of resi-
ues S433 and R619 in UDP-GlcA decarboxylation by
utagenesis and structural analysis. The implication of
his mechanism for the design of selective inhibitors of
rnA is discussed.
esults
rnA Structure Determination
nd Overall Architecture
he oligomeric state of ArnA in solution was deter-
ined by subjecting the purified protein to size-exclu-
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tering analysis. The results showed that ArnA is a
hexamer in solution with no sign of lower-order oligo-
mers in the purified preparation (data not shown). Fur-
thermore, the oligomeric state of the full-length protein
was independent of the presence of substrates. When
expressed separately, the individual transformylase and
dehydrogenase domains of ArnA do not form hexamers
(Gatzeva-Topalova et al., 2004, 2005). The full-length
protein is thus required for hexamerization.
Crystallization of ArnA in the presence of UDP-GlcA
and ATP yielded two different crystal forms from the
same crystallization conditions. One form diffracted to
3.7 Å resolution, and the crystals belonged to rhombo-
hedral space group R3, with two protomers per asym-
metric unit. The second form crystallized in ortho-
rhombic space group P212121, with six protomers per
asymmetric unit and showed diffraction to 3 Å resolu-
tion. We were also able to obtain the rhombohedral
crystal form with the selenomethionine-labeled ArnA
(SeMet). The structure of ArnA was solved by molecular
replacement by using the structures of the ligand-free
ArnA transformylase domain (PBD ID: 1YRW [Gatzeva-
Topalova et al., 2005]) and the ligand-free ArnA dehy-
drogenase domain (PDB ID: 1U9J [Gatzeva-Topalova et
al., 2004]) refined to 1.7 and 2.4 Å resolution, respec-
tively, as search models. The search models repre-
sented approximately one-twelfth of the scattering
mass in the asymmetric unit of the orthorhombic crys-
tals. Therefore, we first determined the position of the
two ArnA protomers in the SeMet rhombohedral crys-
tals by molecular replacement, where the search mod-Table 1. Data Collection and Refinement Statistics
R3 ArnA P212121 ArnA R619M R619Y R619E S433A
Data Collection Statistics
Wavelength (Å) 0. 9795 1.1808 1.54 1.54 1.0781 1.54
Space group R3 P212121 P4132 P4132 P4132 P4132
Cell parameters (Å) a = b = 150.9, a = 151.7, b = 166.2, a = b = c = a = b = c = a = b = c = a = b = c =
c = 218.4 c = 262.0 150.4 150.2 150.3 150.4
Resolution (Å) 30.0–3.70 50.0–3.0 30.0–2.4 30.0–2.7 30.0–2.3 30.0–2.5
Highest resolution shell (Å) 3.83–3.70 3.11–3.0 2.49–2.4 2.8–2.7 2.38–2.3 2.59–2.5
Measured reflections 59,540 (5,914) 166,227 (47,647) 175,106 102,693 180,121 223,475
(16,021) (9,445) (17,703) (21,760)
Unique reflections 18,668 (1,908) 132,644 (13,215) 23,212 (2,262) 16,479 (1,615) 26,139 (2,564) 20,730 (2,010)
I/σ 13.1 (2.4) 14.8 (3.9) 20.7 (4.5) 22.2 (4.6) 21.7 (5.0) 23.2 (4.4)
Redundancy 3.2 (3.1) 1.3 (3.6) 7.5 (7.1) 6.2 (5.8) 6.9 (6.9) 10.8 (10.8)
Data completeness (%) 94.5 (97.0) 99.2 (99.8) 99.8 (99.2) 98.8 (100.0) 99.8 (100.0) 100.0 (100.0)
Rmerge (%) 8.4 (42.3) 7.9 (34.9) 8.6 (43.7) 8.0 (41.0) 9.4 (51.0) 9.7 (57.8)
Refinement Statistics
Rwork 0.225 (0.317) 0.203 (0.242) 0.212 (0.274) 0.200 (0.242) 0.205 (0.258)
Rfree 0.247 (0.334) 0.231 (0.311) 0.260 (0.306) 0.224 (0.253) 0.246 (0.314)
Rmsd from ideal values
Bond lengths (Å) 0.008 0.01 0.01 0.01 0.008
Bond angles (°) 1.42 1.47 1.49 1.45 1.37
Mean B value (Å2) 44.7 37.0 44.5 37.2 41.4
B factor deviation bonds (Å2) 0.97 1.27 1.41 1.22 1.22
B factor deviation angles (Å2) 1.69 2.02 2.30 1.93 2.00
Ramachandran
Residues in favored region (%) 86.1 88.1 88.4 88.7 89.3
Residues in allowed regions (%) 13.9 11.9 11.6 11.3 10.7
Rwork = S|Fobs − Fcalc|/SFobs, where Fobs = observed structure factor amplitude, and Fcalc = structure factor calculated from the model. Rfree
is computed in the same manner as Rwork, by using the test set of reflections. Values for the highest resolution bin are shown in parentheses.els represented approximately one-fourth of the asym-
metric unit scattering mass. An anomalous difference
Fourier map showed positive peaks (with intensities of
3.5 σ or higher) within 2.0 Å of the selenium atoms for
15 out of the 18 Se-methionines in the models confirm-
ing the molecular replacement solutions (the three re-
maining methionines, M11 in one protomer and M11
and M220 in the other protomer, had positive anoma-
lous peaks at 2.27 Å, 2.9 Å, and 3.7 Å from the selenium
atom, respectively). The hexameric biological unit was
generated by applying crystallographic symmetry oper-
ations in the R3 crystals. This hexamer was then used
to solve the structure of the orthorhombic crystals,
which contained one hexamer per asymmetric unit. The
final model is well refined to 3.0 Å resolution (Rwork =
0.225, Rfree = 0.247) with good stereochemistry and
100% of residues lying in the allowed regions of the
Ramachandran plot. Data collection and refinement
statistics are summarized in Table 1.
Both domains of ArnA are generally well defined in
the structure. A short loop in the transformylase domain
(residues 35–42), and the interdomain linker comprising
residues 305–313 could not be traced unambiguously,
presumably due to conformational flexibility (chain D in
the coordinate file shows the most complete interdo-
main linker, missing only residues 309–312).
The hexamer adopts the shape of a three-blade pro-
peller with overall dimensions of 162 × 87 Å (Figure
2). The C-terminal, dehydrogenase domains form the
central core of the particle (light green in Figure 2A),
while the N-terminal, transformylase domains are ar-
ranged on the periphery (dark green in Figure 2A). The
Structure
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ArnA forms a dimer of trimers and adopts the shape of a three-blade propeller.
(A) Ribbon diagram of the ArnA hexamer (top view). The helixes are shown as cylinders. The bottom trimer is colored in gold, and the top
trimer is colored in magenta. One of the monomers is colored differently, such that the ArnA N-terminal transformylase domain is colored in
dark green and the C-terminal dehydrogenase domain is colored in light green.
(B) Side view of the ArnA hexamer (coloring scheme as in [A]).
(C) Top view of the ArnA hexamer colored by temperature factor from purple (lowest) to red (highest). The ligands UDP-GlcA and ATP are
shown as space-filling models (nitrogen is colored in green, oxygen in red, carbon in gray, and phosphorus in yellow).
(D) Cartoon representation of a single ArnA protomer. The ArnA transformylase domain is colored in dark green, and the ArnA dehydrogenase
domain is colored in light green. The ligands are presented as stick models. UDP-GlcA binds in the C-terminal subdomain of ArnA dehydroge-
nase, and the NAD+ analog, ATP, binds in the N-terminal (Rossmann fold) subdomain.dehydrogenase domains in the central core mediate t
tmost of the contacts between protomers within the
hexamer, which can be considered as a dimer of tri- e
imers. The intersubunit contacts in the trimer are domi-
nated by hydrogen bonding and ionic interactions.
hThese include Lys381 and Lys382 from one protomer,
which form salt bridges with Asp368 and Glu366, a
frespectively, from a neighboring protomer, as well as
Glu374, which hydrogen bonds to the main chain amino D
agroups of Ser373 and Glu374 from a second protomer.
The dimerization interface is an extended hydropho- b
2bic surface and includes the formation of a two-
stranded antiparallel β sheet (residues 448–456 from l
otwo adjacent protomers) and a four-helix bundle (resi-
dues 401–423 and 460–480) between two adjacent pro- e
rtomers. The peripheral transformylase domains con-ribute a few interactions to stabilize the hexamer, but
hey are limited compared to those from the dehydrog-
nase domain. The total buried surface in the hexamer
s 22,122 Å2.
As shown in Figure 2C (colored by B factor), the de-
ydrogenase domains in the central core of the particle
re more ordered (with a Bave = 32.2 Å2) than the trans-
ormylase domains in the outer edges (Bave = 60.8 Å2).
uring refinement of the structure, the presence of ATP
nd UDP-GlcA bound to the dehydrogenase domains
ecame evident and were added to the model (Figure
D). Well-defined electron density is observed for the
igands in the final model (Figure 3). The conformations
f the individual domains from all six protomers are
ssentially identical, superimposing with an average
ms deviation of 0.18 Å for the transformylase domains,
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The maps are Fo − Fc simulated annealing omit maps, computed with phases calculated from models in which the ligands were omitted.
(A) Electron density in the ATP binding site contoured at 5σ. The protein is shown as a ribbon diagram colored in magenta, and the refined
substrate model is superimposed on the density for reference.
(B) Electron density for the UDP-GlcA binding site contoured at 5σ, colored as in (A).and 0.33 Å for the dehydrogenase domains for all Cα
atoms. While NCS restraints were used throughout the
refinement process (see the Experimental Procedures),
the weight of those restrains was reduced to 40 Kcal
mol−1 A−2 for the transformylase domain and 80 Kcal
mol−1 A−2 for the dehydrogenase domain in the final
rounds of refinement. In addition, inspection of the
electron density in a simulated annealing composite
omit map did not reveal deviations of any of the pro-
tomers from the electron density. We therefore consider
all protomers conformationally equivalent and focus
our further analysis on the features of the individual do-
mains of a single protomer.
The conformation of the transformylase domain is
very similar in the full-length structure presented here
and in that of the isolated domain (Gatzeva-Topalova et
al., 2005). The two structures superimpose with an rms
deviation of 0.66 Å. In contrast, the structure of the li-
gand-free dehydrogenase domain shows striking differ-
ences from the ligand bound structure observed in the
full-length hexamer (see below).
Conformational Changes in the ArnA
Dehydrogenase Domain
A comparison of the structures of the ArnA dehydroge-
nase domain in the presence and absence of ligandsreveals a striking conformational change (Figure 4). In
the previously determined ligand-free structure, resi-
dues 500–509 define a loop that blocks the NAD+ bind-
ing site. In contrast, in the presence of UDP-GlcA and
the NAD+ analog ATP, this segment of polypeptide
forms a short helix that folds over the UDP-GlcA (L1 in
Figure 4B). The Cα atom of residue I506 in the center
of this loop is displaced by 17.5 Å between the two
structures, illustrating the magnitude of the conforma-
tional change. It is important to note that this region of
the structure is not involved in any interactions with the
transformylase domain, nor is it involved in any lattice
contacts in this ligand bound structure or in the pre-
viously determined ligand-free structure. The confor-
mational change thus appears to be induced by ligand
binding and has two important consequences: (i) it
opens the NAD+ binding site (which in our structure is
occupied by ATP) (Figures 4A and 4C); and (ii) it effec-
tively traps the UDP-GlcA in its binding site (Figures 4B
and 4D).
Another important conformational change occurs in
the region defined by amino acids 605–616. In the li-
gand-free structure, electron density for this segment
of the polypeptide was ill defined and could not be
modeled, suggesting conformational flexibility. Upon
binding of UDP-GlcA, S –Y become ordered into a606 609
Structure
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(A) Structure of the ligand-free ArnA dehydrogenase domain (PDB_ID: 1U9J). The 500–509 loop that blocks the NAD+ binding site is colored
in magenta. The disordered loop, loop 605–616, is shown as a dotted line colored in magenta.
(B) Structure of the ATP/UDP-GlcA ligand bound ArnA_DH domain. The 500–509 loop (L1) is displaced 17 Å (measured at the Cα of the central
residue I506) compared to the ligand-free structure, opening the NAD+ binding site. The 605–616 loop becomes ordered into a one-turn helix,
followed by a loop that lines the UDP-GlcA binding site (L2).
(C) Transparent surface model of the ligand-free ArnA dehydrogenase domain. For reference, the positions of the two ligands from the ligand
bound structure are shown as blue sticks. The 500–509 loop is colored in yellow, blocking the NAD+ binding site, while the UDP-GlcA binding
site appears open. Residues 604 and 617, which represent the ends of the disordered 605–616 loop, are also colored yellow.
(D) Transparent surface model of the ATP/UDP-GlcA bound structure. Both ligands are presented as blue sticks. A large conformational
change in the 500–509 region, as well as stabilization of the 605–616 region, opens the NAD+ binding site but effectively traps UDP-GlcA in
its active site.one-turn helix followed by a loop that makes several s
scontacts with the uracil ring of UDP-GlcA (L2 in Figure
4). This conformational change also contributes to the s
Mtrapping of UDP-GlcA in its binding site. Like in the
case of the 500–509 loop, this region is not involved in a
any interdomain or crystal contacts. Therefore, it ap-
pears to be triggered by UDP-GlcA binding. S
DSeveral smaller conformational changes are also ob-
served in the ligand bound structure of ArnA. They can T
mbe visualized, from a more global perspective, as amall hinge motion between the two dehydrogenase
ubdomains such that the protein closes in around the
ubstrates to form a more compact structure (see
ovie S1 in the Supplemental Data available with this
rticle online).
ubstrate Binding Sites in ArnA
ehydrogenase Domain
he crystal structure of ArnA presented here was deter-
ined in the presence of the dehydrogenase substrate
Structure of ArnA: Mechanism of Dehydrogenation
935UDP-GlcA and ATP. The second dehydrogenase sub-
strate NAD+ contains an ADP moiety, and ATP can act
as a close structural mimic of NAD+ as a result. Very
clear density for both ligands was observed in the de-
hydrogenase domain of ArnA (Figure 3).
The dehydrogenase active site is situated in a cleft
formed between the two subdomains of ArnA_DH (Fig-
ure 2D). The binding site for NAD+ (occupied by ATP in
our structure) is located mainly in the N-terminal (Ross-
mann fold) subdomain of ArnA_DH, as observed in
many other dinucleotide binding proteins (Figure 2D).
As shown in Figure 5A, the adenosine moiety resides in
a hydrophobic pocket formed by residues L321, L346,
I348, I369, V390, I392, and L408. It also forms hydrogen
bonds with the side chain of D368 and the main chain
nitrogen of I369. The ribose and phosphate groups are
stabilized by additional hydrogen bonding interactions
with the side chain oxygen of D347, and the main chain
amides of G325, F326, and I327.
The UDP-GlcA binding site resides mainly in the
C-terminal subdomain of ArnA_DH, where it makes a
number of hydrogen bonding contacts with the protein
(Figures 2D and 5B). The uracil moiety hydrogen bonds
the main chain atoms of K256 and I528. The ribose con-
formation is stabilized by hydrogen bonding the side
chains of Q533 and Y613, while the α and β phosphates
are fixed in place by several hydrogen bonds to R460,
R535, and the catalytic R619 (see below). The protein
also makes seven hydrogen bonds with the glucuronicFigure 5. Substrate Binding Sites in the ArnA_DH
(A) The ATP binding site. The adenosine ring lies in a hydrophobic pocket formed by residues I321, L346, I348, I369, V390, I392, and L408 (colored
in yellow). Residues of the protein that contribute hydrogen bonding interactions are colored in green.
(B) The UDP-GlcA binding site. Protein residues forming hydrogen bonds with the substrate are colored in green.acid moiety, presumably positioning it in the right con-
formation for catalysis. The 2$ hydroxyl of the GlcA
contacts Y398, while the 4$ hydroxyl is within hydrogen
bonding distance of Oγ1 of T432, a conserved residue in
SDR enzymes that catalyze NAD+-dependent oxidation
of the 4$ hydroxyl. The carboxyl group of UDP-GlcA
that leaves as carbon dioxide during catalysis displays
hydrogen bond interactions with the backbone nitrogen
of N492 as well as with the side chains of S433 and R619.
These two residues were previously suggested to play
a role in substrate binding and/or catalysis (Gatzeva-
Topalova et al., 2004).
Role of S433 and R619 in the Oxidative
Decarboxylation Reaction Catalyzed
by ArnA Dehydrogenase
We have previously proposed that S433 and R619 may
play a role in the decarboxylation reaction catalyzed by
ArnA dehydrogenase (Gatzeva-Topalova et al., 2004).
This proposal was based on the strict conservation of
these residues in all enzymes catalyzing UDP-GlcA de-
carboxylation and the fact that residues at equivalent
positions in other SDR enzymes have been shown to
play important roles in substrate binding and catalysis.
In addition, modeling studies suggested that S433 and
R619 would be well positioned to interact with the UDP-
GlcA carboxylate (Gatzeva-Topalova et al., 2004). In-
deed, the ATP/UDP-GlcA ligand bound structure of the
Structure
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mand R619 to be 3.5 Å from the UDP-GlcA carboxylate.
zThe potential role of S433 and R619 in the decarboxyl-
cation reaction was investigated by preparing a series of
upoint mutants (S433A, S433T, R619M, R619Y, and
hR619E) of the isolated ArnA_DH domain (amino acids
p306–660). The activity of the mutants was compared to
athe wild-type ArnA_DH domain by using a spectropho-
ftometric assay under conditions that are saturating for
tthe wild-type enzyme (see legend in Table 2). The re-
asults, summarized in Table 2, show that all mutants had
sundetectable or dramatically reduced activity, support-
iing a role for these residues in substrate binding and/
gor catalysis. While the R619Y and R619E mutants had
dno activity, S433A and R619M showed residual activi-
(ties 30- and 800-fold lower than the wild-type, respec-
atively. Surprisingly, The S433T mutant had no detecta-
dble activity. The S433A and R619M mutants were also
ievaluated at UDP-GlcA concentrations 5-fold higher
dthan the standard assay. This condition represents a
substrate concentration more than 90-fold the apparent
lKm for UDP-GlcA in the wild-type enzyme. As shown in
lTable 2, the 5-fold increase in substrate concentration
sresulted in a modest 2-fold increase in the activity of
zthe R619M mutant and had no effect on the activity of
(the S433A mutant. These results suggest that, while
HS433 and R619 may play a role in substrate binding and
tcontribute to the affinity of the enzyme for UDP-GlcA,
tthe dramatic loss of activity is likely due to their role
sin catalysis.
tTo rule out enzyme misfolding as a factor in the lack
aof activity in our mutants, crystallization experiments
twere set up for all the mutant proteins under conditions
tthat had previously resulted in successful crystalliza-
btion of the isolated wild-type ArnA_DH domain (Gat-
zeva-Topalova et al., 2004). In spite of repeated efforts,
the S433T mutant failed to crystallize, suggesting that C
Tthe lack of activity in this mutant may be due to im-
proper folding. By contrast, crystals were immediately A
sobtained for the rest of the mutants, and their struc-
tures were solved and refined by using difference Fou- (
frier methods as detailed in the Experimental Procedures.
A superposition of the mutant structures with the wild- a
stype shows no significant conformational changes due totTable 2. Activity of ArnA Dehydrogenase Mutants
w
Fold t
Rate, Decrease r
Enzyme nmolNADH.mgEz−1.min−1 in Activity c
Wild-type ArnA _DH 215.9 ± 0.4 – i
S433A (1 mM UDP-GlcA) 6.33 ± 0.03 30 t
S433A (5 mM UDP-GlcA) 6.43 ± 0.10 30
tR619M (1 mM UDP-GlcA) 0.26 ± 0.05 800
SR619M (5 mM UDP-GlcA) 0.51 ± 0.10 400
R619Y (1 mM UDP-GlcA) 0.02 ± 0.02 >10000
S433T (1 mM UDP-GlcA) 0.01 ± 0.02 >10000 D
R619E (1 mM UDP-GlcA) 0.00 ± 0.02 >10000
The activity of the mutants was measured spectrophotometrically A
by detecting the increase of absorbance at 340 nm due to the f
release of NADH. The substrates UDP-GlcA and NAD+ were used r
at saturating concentrations (UDP-GlcA, 1 or 5 mM; NAD, 3 mM)
2for the wild-type enzyme (Km, app [NAD] = 0.57 ± 0.09 mM; Km, app
d[UDP-GlcA] = 0.054 ± 0.003 mM [Gatzeva-Topalova et al., 2004]).
h
the substitutions. The mutant structures superimpose
ith the wild-type ArnA_DH fragment with rms devia-
ions between 0.1 and 0.25 Å for all Cα atoms. In the
egion of the structure in which the mutations are lo-
ated (amino acids 432–434 and 619–621), they super-
mpose with an average rms deviation of 0.21 Å. We
herefore conclude that the loss of activity in the mu-
ants (except S433T) is a bona fide effect of the role of
433 and R619 in enzyme catalysis.
iscussion
rnA is a required enzyme in the pathway for the modi-
ication of lipid A with Ara4N that leads to antimicrobial
esistance in gram-negative bacteria (Breazeale et al.,
005). ArnA is bifunctional. It catalyzes the oxidative
ecarboxylation of UDP-GlcA with its C-terminal de-
ydrogenase domain (the first pathway-specific reac-
ion). Formyl transfer from N10-formyltetrahydrofolate
o UDP-Ar4N is catalyzed by the N-terminal transfor-
ylase domain of ArnA (Breazeale et al., 2005; Gat-
eva-Topalova et al., 2005). ArnB, a separate enzyme,
atalyzes the intervening transamination reaction (Fig-
re 1). The biochemical and structural data presented
ere show that ArnA forms a hexameric structure com-
rising a dimer of trimers. The dehydrogenase domains
re arranged at the center of the particle, with the trans-
ormylase domains on the outer edges (Figure 2A). Lit-
le interaction is observed between the two domains,
nd the oligomerization does not appear to introduce
tructural changes that would affect the activity of the
ndividual domains. This is illustrated by the high de-
ree of structural similarity between the transformylase
omain in the hexamer with that of the isolated domain
rms deviation of 0.66 Å for 97% of the Cα atoms). It is
lso in agreement with the observation that the dehy-
rogenase activity of the full-length hexameric enzyme
s indistinguishable from that of the isolated dehy-
rogenase domain (Gatzeva-Topalova et al., 2004).
Since ArnA catalyzes the first and third steps in the
ipid A-Ara4N biosynthetic pathway while ArnB cata-
yzes the second step (Figure 1), it is tempting to
peculate that these enzymes may form a multien-
yme complex in which substrates could be channeled
Breazeale et al., 2005; Gatzeva-Topalova et al., 2005).
owever, no data are yet available supporting the exis-
ence of such a complex. It is also possible that addi-
ional enzymes in the pathway may be needed for as-
embly of this complex. It is tempting to speculate that
he hexameric structure of full-length ArnA may act as
scaffold for a complex. Further work characterizing
he biochemistry and interactions of enzymes within
his pathway is required to explore this intriguing possi-
ility.
onformational Changes upon Substrate Binding
he comparison of the ligand-free structure of the
rnA_DH domain with the ligand bound structure pre-
ented here highlights a striking conformational change
Figure 4). In the ligand-free structure, the binding site
or UDP-GlcA is open, while a loop defined by amino
cids 500–509 occupies the NAD+ binding site. This ob-
ervation led to the proposal that UDP-GlcA would bind
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937the enzyme first, inducing a conformational change that
would open the NAD+ binding site (Gatzeva-Topalova
et al., 2004). The ligand bound structure presented here
shows a 17 Å displacement of the 500–509 loop, effec-
tively opening the NAD+ binding site, and provides
strong support for the above-described hypothesis. In
the ligand bound structure, the NAD+ site is occupied
by ATP (an NAD+ analog). Interestingly, the ligand
bound structure also highlights an unpredicted conse-
quence of the conformational change. The new confor-
mation of the 500–509 polypeptide and the ordering of
the 605–616 region effectively trap UDP-GlcA in the
active site (Figures 4B and 4D). This observation might
help rationalize the differences between ArnA dehy-
drogenase and a family of related eukaryotic enzymes
that also catalyze UDP-GlcA decarboxylation.
The oxidative decarboxylation of UDP-GlcA is cata-
lyzed in many eukaryotes, including humans, by en-
zymes alternatively known as UDP-GlcA decarboxyl-
ases or UDP-Xylose synthases (Bar-Peled et al., 2001;
Harper and Bar-Peled, 2002; Moriarity et al., 2002; Pat-
tathil et al., 2005). These enzymes use NAD+ to oxidize
the 4$ hydroxyl of UDP-GlcA, followed by decarboxyl-
ation, just as in ArnA. However, in UDP-Xylose syn-
thases, the decarboxylated 4-keto sugar is then rere-
duced by NADH to generate UDP-Xylose (Figure 6B).
Therefore, NAD+ is utilized as a coenzyme and does
not need to be added exogenously for the reaction to
proceed (Bar-Peled et al., 2001). In contrast, ArnA uses
NAD+ as a true substrate that is consumed to release
NADH and the decarboxylated UDP-4-keto-pentose
(Figure 6A) (Gatzeva-Topalova et al., 2004). The fact
that UDP-GlcA appears trapped in the active site of
ArnA, while the NAD+ binding site remains open, sug-
gests that, after the oxidation reaction takes place,
NADH could be released from the enzyme. This implies
an ordered reaction mechanism in which UDP-GlcA
would bind first, followed by NAD+ binding, and oxida-
tion of the 4$ hydroxyl. The resulting NADH would be
released from the enzyme first, preventing the rereduc-
tion of the 4$ ketone. This strategy would allow the en-
zyme to generate the correct UDP-4-keto-pentose
product instead of UDP-Xylose. While this model is
compatible with the available structural evidence, it
awaits corroboration by a full kinetic characterization
of ArnA dehydrogenase.
Substrate Binding in ArnA Dehydrogenase
Compared to Other SDR Enzymes
ArnA dehydrogenase belongs to the short-chain dehy-
drogenase/reductase (SDR) family of enzymes thatFigure 6. Enzymes Catalyzing the Oxidative
Decarboxylation of UDP-GlcA
(A) ArnA dehydrogenase domain. In this en-
zyme, NAD+ is used to oxidize UDP-GlcA to
UDP-4-keto-hexauronic acid with the release
of NADH.
(B) UDP-Xylose synthases. These enzymes
use NAD+ as a cofactor. It is utilized to oxi-
dize the 4$ hydroxyl of UDP-GlcA just as in
ArnA_DH. However, the decarboxylated 4-keto-
pentose is rereduced by NADH to gener-
ate UDP-Xylose without net consumption of
NAD+.catalyze NAD(P)+-dependent dehydrogenase reactions
with various sugar nucleotides (Jornvall et al., 1995).
The E. coli enzyme UDP-Galactose epimerase (GALE)
has been extensively studied both structurally and
mechanistically, and it is perhaps the best-charac-
terized member of the SDR family (Thoden et al., 1996a,
1996b, 1996c, 1997a, 1997b, 2000, 2002; Thoden and
Holden, 1998). Comparison of ArnA_DH with GALE al-
lowed the modeling of UDP-GlcA and NAD+ binding to
ArnA (Gatzeva-Topalova et al., 2004). The current ligand
bound structure confirms the location of the active site
and provides a refined view of the substrate binding
determinants.
Interestingly, the residues responsible for UDP-GlcA
binding (Figure 5B) are well conserved not only in ArnA
orthologs from other bacteria, but also in all UDP-
Xylose synthases mentioned above (with the exception
of Y613, which is part of a four amino acid insertion in
ArnA not present in the UDP-Xylose synthases) (see
[Gatzeva-Topalova et al., 2004] and its supplemental
data). However, those residues are not conserved in
GALE in spite of binding a substrate similar to that of
ArnA (GALE binds UDP-glucose/galactose instead of
UDP-GlcA). This is likely due to the fact that SDR en-
zymes catalyzing epimerization reactions, like GALE
and WbpP, need to flip the sugar ring about the bond
linking the glycosidic oxygen and the β phosphate to
accomplish epimerization (Ishiyama et al., 2004; Tho-
den et al., 2002). Therefore, it is advantageous for those
enzymes to have a loose-fitting sugar binding pocket
that can accommodate ring flipping (Ishiyama et al.,
2004). Since no ring flipping is required for the oxida-
tive decarboxylation reaction catalyzed by ArnA, more
stringent binding of the glucuronate moiety is likely to
constrain the substrate to a catalytically favorable con-
formation. In addition, mutating residue R619 in ArnA
to the corresponding residue in GALE (R619Y) not only
completely abolished decarboxylation, but also failed
to catalyze epimerization to UDP-Galacturonic acid
(data not shown), further suggesting tighter binding of
the sugar ring in ArnA compared to epimerases.
Many residues involved in NAD+ binding by SDR en-
zymes are retained in ArnA dehydrogenase. However,
the total number of contacts between the protein and
the ADP moiety (the moiety common to NAD+ and the
ATP bound in the ligand bound structure) is smaller in
ArnA than in GALE (8 in ArnA versus 17 in GALE). This
is in agreement with ArnA using NAD+, which is bound,
reduced, and released as NADH, as a true substrate,
while GALE uses NAD+ in a full reaction cycle (like UDP-
Xylose synthase) as a coenzyme that remains tightly
Structure
938bound to the enzyme at all times (Ishiyama et al., 2004; a
lThoden et al., 1996a, 1996b, 1996c, 1997b).
d
cA Putative Catalytic Mechanism
wfor ArnA Dehydrogenase
fThe reaction catalyzed by the ArnA dehydrogenase do-
2main is a two-step process that includes: (i) the NAD+-
5dependent oxidation of the UDP-GlcA C4$ position,
aand (ii) decarboxylation of the β-ketoacid to yield UDP-
m4-keto-pentose (Figure 6).
RThe first step is similar to the oxidation step cata-
ilyzed by many SDR enzymes, including GALE, dTDP-
(D-Glucose 4,6-Dehydratase, and ADP-L-glycero-D-man-
tnoheptose 6-epimerase, among others. The reaction
1mechanism has been extensively studied in these en-
a
zymes (Allard et al., 2001; Babbitt et al., 1995; Beis et
t
al., 2003; Deacon et al., 2000; Thoden et al., 1997a,
2000; Vogan et al., 2004). In all cases, a serine/threo- u
nine-tyrosine-lysine catalytic triad was shown to be re- c
sponsible for catalysis. In ArnA dehydrogenase, these b
three residues correspond to T432, Y463, and K467 and a
are structurally conserved (Gatzeva-Topalova et al., p
2004). Therefore, the first step in ArnA catalysis is likely a
to proceed by a similar mechanism. In this model, Y463 t
acts as the general base catalyst abstracting a proton p
from the 4$-OH of UDP-glucuronate either directly or n
through a proton relay mechanism facilitated by T432 R
(Gatzeva-Topalova et al., 2004; Thoden et al., 2000). In t
the ligand bound structure of ArnA, the Oγ of T432 is w
2.5 Å away from the 4$-OH of the substrate, while the r
Oη of Y463 is almost 5 Å away. Therefore, a proton relay t
mechanism is very likely at play in ArnA. The third resi- i
due in the triad, K467, would lower the pKa of Y463 and t
enhance the reactivity of NAD+ (Swanson and Frey, f
1993) that accepts hydride transfer from the sugar C4$, l
yielding the UDP-4-keto-hexauronic acid intermediate u
(Figure 6). e
The decarboxylation of the UDP-4-keto-hexauronic c
acid intermediate is the second step in the reaction that a
yields the final product, UDP-4-keto-pentose. The mu-
tagenesis results presented here suggest a catalytic I
role for residues R and S in the decarboxylation BFigure 7. Proposed Mechanism for the UDP-
4-Keto-Hexauronic Acid Decarboxylation
The substrate, UDP-GlcA, is first oxidized at
the glucosyl C4$ by NAD+ to generate UDP-
4-keto-hexauronic acid. Residues S433 and
R619 initially hydrogen bond to the carboxyl
group of UDP-GlcA. The formation of carbon
dioxide is accompanied by the formation of
an enolate intermediate that would adopt a
half chair conformation, bringing the 4$ oxy-
gen closer to S433 and R619. The developing
negative charge may be stabilized by the
positive change of R619 and hydrogen bond-
ing to S433. The residue R619 may function as
a general acid, donating a proton to the
C5$ to yield the final product, UDP-4-keto
pentose.619 433
step. While it is possible that the mutations affect theffinity of the enzyme for the UDP-GlcA, the following
ines of evidence support a catalytic role for the resi-
ues: (i) the activity measurements were carried out at
oncentrations of substrates that are saturating for the
ild-type enzyme ([UDP-GlcA] = 1 mM, more than 15-
old its apparent Km of 54 M [Gatzeva-Topalova et al.,
004]); (ii) increasing the UDP-GlcA concentrations
-fold had no effect on the activity of the S433A mutant
nd only a minor effect in the activity of the R619M
utant; (iii) the alternative R619 mutants R619Y and
619E had undetectable activity even after overnight
ncubations; and (iv) these residues contribute only one
S433) or two (R619) hydrogen bonding interactions be-
ween ArnA and UDP-GlcA (Figure 5) out of a total of
5. We therefore consider it unlikely that R619 and S433
re only involved in substrate binding instead of ca-
alysis.
We propose a mechanism for UDP-4-keto-hexa-
ronic acid decarboxylation in which R619 and S433 play
atalytic roles as depicted in Figure 7. In this model,
oth S433 and R619 initially hydrogen bond the carboxyl-
te group of UDP-GlcA. The decarboxylation reaction
roceeds via an enolate intermediate that would adopt
half chair conformation bringing the 4$ oxygen closer
o S433 and R619. Ser433 and the positive charge of the
rotonated R619 may help stabilize the developing
egative charge in the 4$ oxygen, while the protonated
619 functions as a general acid, donating a proton to
he C5# to yield the final product. The R619M mutant
ould not be able to serve as a general acid, and its
esidual activity may be due to much less efficient pro-
on transfer from the bulk solvent or a nearby residue
n the active site. Inspection of the active site shows
hat the side chain carboxylate of E434 is 4.8 Å away
rom the C5# of UDP-GlcA. However, this residue is un-
ikely to be protonated at neutral pH and would thus be
nable to serve as a general acid. Saturation mutagen-
sis studies would be required to fully assess the pre-
ise role of each residue in the active site (Warren et
l., 1996).
mplications for Inhibitor Design
oth the dehydrogenation and transformylation reac-tions catalyzed by ArnA are required for lipid A modifi-
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939cation with Ara4N and bacterial resistance to polymyxin
(Breazeale et al., 2005; Roland et al., 1993, 1994; Shafer
et al., 1984). This makes ArnA a good potential target
for the design of new anti-infective compounds. Such
inhibitors would make bacteria more susceptible to the
antimicrobial activity of CAMPs and antibiotics of the
polymyxin family. However, given the substrate similari-
ties between ArnA_DH and human enzymes like UDP-
Xylose synthase, the design of selective inhibitors may
prove challenging. We propose that the substrate-
induced conformational changes described here may
provide a route to inhibitor selectivity. Since UDP-
Xylose synthases use NAD+ in a full reaction cycle, they
are likely to have the NAD+ coenzyme very tightly
bound at all times, as observed for SDR enzymes that
utilize NAD+ in this manner. If the proposed ordered
mechanism for ArnA is correct, UDP-GlcA analogs with
extended groups at the 4$ position of the sugar may
be able to bind preferentially to ArnA. They would oc-
cupy the UDP-GlcA site and part of the nicotinamide
binding site that would be free in ArnA, but not in UDP-
Xylose synthases. We await the synthesis of such ana-
logs to test this intriguing hypothesis.
Experimental Procedures
Protein Purification
The ArnA full-length and ArnA dehydrogenase domains were ex-
pressed and purified as described previously (Gatzeva-Topalova et
al., 2004). Point mutations in the ArnA dehydrogenase domain
(R619M, R619Y, R619E, S433A, and S433T) were introduced by
using the QuickChange site-directed mutagenesis kit (Stratagene)
according to the manufacturer’s instructions. During the mutagene-
sis procedure, a unique restriction site was also introduced (by si-
lent mutation) next to the site of the point mutation to facilitate the
selection of clones containing the mutant. After the introduction of
the mutation, the vector was transformed into E. coli XL-10 cells
(Stratagene) and plated on LB kanamycin plates. Plasmids were
isolated by using the QIAprep Spin Miniprep kit (Qiagen). Clones
carrying the mutation were identified by restriction digest taking
advantage of the introduced unique restriction sites and were se-
quenced to ensure the absence of random mutations. The resulting
mutants were overexpressed and purified as described for the
wild-type ArnA dehydrogenase domain (Gatzeva-Topalova et al.,
2004).
Expression of Selenomethionine-Labeled ArnA Full-Length
The plasmid pETArnA (a generous gift from Prof. C. Raetz) was
transformed into E. coli Rosetta (DE3) cells (Novagen). A 50 ml cul-
ture from a single colony containing 30 g/ml kanamycin was
grown overnight at 37°C. Two 10 ml aliquots were taken, spun
down to remove LB media, and resuspended in 10 ml M9 minimal
media supplemented with 30 g/ml kanamycin. The resuspended
bacterial pellets were used to start two 1 liter cultures in M9 mini-
mal media containing 30 g/ml kanamycin and were grown at 37°C
to an OD600 of w0.6. At that point, the flasks were moved to room
temperature, and methionine synthesis was inhibited by adding
100 mg/l D-lysine, D-phenylalanine, and D-threonine and 50 mg/l
D-isoleucine and D-valine. In addition, 60 mg/l D/L selenomethio-
nine (Se-Met, Sigma) was added. After 20 min, protein expression
was induced with 0.4 mM isopropyl-1-β-D-thiogalactopyranoside
(IPTG, Gold Bio Technology, Inc.) and grown for 6 hr at room tem-
perature. Cells were harvested by centrifugation, and the protein
was purified as described for wild-type ArnA (Gatzeva-Topalova et
al., 2004). The level of Se-Met incorporation was 88% as deter-
mined by amino acid analysis (AAA Service Laboratory, Inc.).
ArnA Full-Length: Crystallization and Data Collection
ArnA full-length was preincubated for 30 min on ice with 3 mM
UDP-GlcA and 3 mM MgSO4 to give a final concentration of 6.0
mg/ml. Crystallization was attempted by the hanging drop methodof vapor diffusion at 16°C (protein:precipitant ratio of 2.0 l:2.0 l).
A condition consisting of 0.1 M MES (pH 7.0), 10% ethylene glycol,
9% polyethylene glycol 8000, 14 mM 2-mercaptoethanol, and 10
mM ATP yielded two different crystal forms with rhombohedral and
orthorhombic morphologies. Initial diffraction analysis showed that
the rhombohedral crystals belonged to space group R3 and typi-
cally diffracted to 3.5–4.0 Å resolution with slight anisotropy. Unit
cell dimensions for these crystals were a = b = 150.9 Å, c =
218.4 Å, α = β = 90°, γ = 120° and contained two molecules per
asymmetric unit (solvent content = 61.5%). The orthorhombic crys-
tals belonged to P212121 space group, with typical unit cell dimen-
sions of a = 151.7, b = 166.2, c = 262.0, α = β = γ = 90° and six
molecules per asymmetric unit (solvent content of 66.5%). These
orthorhombic crystals diffracted to w3.0 Å resolution at a synchro-
tron source. Crystallization of Se-Met-labeled protein was also at-
tempted. We were only able to obtain the R3 crystal form with Se-
Met-labeled protein after optimizing the crystallization conditions
to 0.1 M MES (pH 6.75), 8% ethylene glycol, 9% polyethylene glycol
8000, 5 mM DTT, and 10 mM ATP. These crystals diffracted to the
same resolution as the native crystals.
Prior to X-ray data collection, the Se-Met R3 crystals were trans-
ferred to a cryoprotecting solution composed of mother liquor con-
taining 3 mM UDP-GlcA, 3 mM MgSO4, and 15% w/v dextrose,
soaked for 3 min, then transferred to the same cryoprotecting solu-
tion containing 30% w/v dextrose and flash cooled to 100°K in a
nitrogen gas stream. P212121 crystals were cryoprotected in mother
liquor containing 3 mM UDP-GlcA, 3 mM MgSO4, and 25% v/v
glycerol, soaked for 1 hr, and flash cooled in a nitrogen stream. A
3.7 Å data set from the Se-Met-labeled R3 crystals and a 3.0 Å data
set for the native P212121 crystals were collected on beam line 8.2.2
at the Advanced Light Source at Lawrence Berkeley National Labo-
ratory. Data were indexed and integrated with DENZO and scaled
with SCALEPACK (Otwinowski and Minor, 1997). X-ray data collec-
tion statistics for both sets are shown in Table 1.
ArnA Full-Length: Structure Determination and Refinement
The structure of ArnA was solved by molecular replacement by
using the structures of the individual domains solved previously
to 1.7 Å (ArnA transformylase domain, PDB ID: 1YRW [Gatzeva-
Topalova et al., 2005]) and 2.4 Å (ArnA dehydrogenase domain,
PDB ID: 1U9J [Gatzeva-Topalova et al., 2004]) as search models.
Rotation/translation searches were performed with the program
AMoRe (Navaza, 2001) and data between 15 and 4.5 Å using the
R3 data set collected at the peak absorption wavelength of Se (λ =
0.9795). This data set was chosen despite the lower resolution be-
cause it contained only two protomers per asymmetric unit, com-
pared to six in the case of the better diffracting P212121 crystals.
Rotation/translation searches allowed the location of two ArnA_DH
molecules and one of the ArnA_TF molecules. Noncrystallographic
symmetry (NCS) operation relating the two copies of ArnA_DH was
computed and used to place the second copy of ArnA_TF in the
asymmetric unit. Inspection of the crystal packing revealed no un-
favorable molecular contacts. Prior to refinement with the program
CNS (Brünger et al., 1998), 10% of the data were removed for
crossvalidation. Several rounds of rigid body refinement followed
by simulated annealing with torsion angle dynamics (Brünger et al.,
1990, 1997) and domain B factor refinement dropped the Rwork from
47.8% to 35.0% and the Rfree from 48.6% to 41.7%. At this point,
phases derived from the model were used to compute an anoma-
lous difference Fourier map. Most methionines in both copies of
the ArnA_DH and ArnA_TF domains coincided with anomalous dif-
ference peaks. Crystallographic symmetry operations applied to
the model allowed the assembly of the biological hexamer, which
was then used as a search model to solve the structure of the
orthorhombic crystals by molecular replacement. Rotation/transla-
tion searches were again performed with the program AMoRe and
data to 5 Å resolution, which yielded three equivalent solutions re-
flecting the 3-fold symmetry of the model. The same three solutions
were obtained by using data in various resolution shells, and, in
every case, they were well above the noise level. Prior to refine-
ment with CNS, 10% of the data were removed for crossvalidation.
The model was subjected to a round of rigid body refinement fol-
lowed by domain B factor refinement with data to 4.0 Å. Model
phases were improved by solvent flipping, as implemented in CNS
Structure
940(solvent content of 66%), and were used to compute an F0 P
texp(αcalc) map. All models coincided generally well with the
electron density, with the exception of one copy of the ArnA_TF R
domain, which appeared to be displaced from the density. A round
of rigid body refinement with the MLHL target function (maximum S
olikelihood with the solvent-flipped phase probability distribution)
locked the stray ArnA_TF domains in the correct position. Tight T
2(300 kcal mol−1 Å−2) noncrystallographic symmetry (NCS) restrains
were set up with separate operators relating ArnA_DH and ArnA_ m
wTF domains. The model was then subjected to rounds of simulated
annealing with torsion angle dynamics and group B factor refine- A
tments with data to 3.2 Å resolution. At this point, the R factor was
0.322 (Rfree = 34.5). Model phases were again improved by solvent f
vflipping, and a new electron density map was calculated. Inspec-
tion of the map revealed a significant conformational change in
residues 500–509 as well as clear density for residues 605–616,
which were missing in our model. These regions were manually S
rebuilt with the program O (Jones, 1978). The model was subjected
to several rounds of simulated annealing with Cartesian dynamics, S
tfollowed by positional and B factor refinement with NCS restrains.
Iterative rounds of manual rebuilding followed by positional and B a
factor refinement in which the NCS restrains were progressively
relaxed were performed until no further improvement of the Rfree A
factor was observed (Rwork of 0.243 and Rfree of 0.261). At this
point, electron density maps showed clear density for ATP and W
aUDP-GlcA molecules in the dehydrogenase domain of each of the
protomers, and they were added to the model. The final rounds of c
cpositional and atomic B factor refinement were carried out with
NCS restrains relaxed to 40 kcal mol−1 Å−2 (ArnA_TF domain) and e
s80 kcal mol−1 Å−2 (ArnA_DH domain). The final model (Rwork of 0.225
and Rfree of 0.247) has good stereochemistry, as determined by (
Nusing the program PROCHEK (Laskowski et al., 1993), with all
amino acids lying in the most favorable or allowed regions on the U
fRamachandran plot. No electron density was observed for residues
35–42 in the transformylase domain or residues 305–313 in the in-
terdomain linker (in chain D, the missing residues for the interdo- R
main linker are 309–312). Refinement statistics and model stereo- R
chemistry are summarized in Table 1. A
P
ArnA Dehydrogenase Mutants: Structure Determination
RCrystals of ArnA_DH mutants—R619M, R619Y, R619Mk and
S433A—were obtained from conditions identical to those used for
Athe wild-type ArnA_DH (Gatzeva-Topalova et al., 2004). Crystalliza-
ation conditions were 2.0–2.1 M (NH4)2SO4, 5 mM DTT, 100 mM MES
4(pH 6.75). For one of the mutants—S433T—we were not able to
robtain crystals under these conditions. Like the wild-type ArnA_
BDH, all crystals belonged to space group P4132, with dimensions
Bsimilar to those of the wild-type protein (Table 1). Crystals were
Rcryoprotected as previously described (Gatzeva-Topalova et al.,
f2004). Data were collected with a rotating anode generator by
pusing CuKα radiation and a Rigaku RAXIS IV2+ detector, and on
beam line 8.2.2 at the Advanced Light Source at Lawrence Berke- B
ley National Laboratory. Data were indexed and integrated with m
DENZO and scaled with SCALEPACK (Otwinowski and Minor, d
1997). X-ray data collection statistics are shown in Table 1. c
Prior to refinement with CNS, 10% of the data for each mutant B
was removed for crossvalidation. The model (ArnA_DH domain) c
was subjected to rigid body refinement followed by simulated an- a
nealing with Cartesian dynamics and several rounds of positional U
and B factor refinement. To reduce model bias, model phases were
Bimproved by solvent flipping. Inspection of the resulting map re-
Nvealed no major difference between the wild-type and the mutant
dproteins. Refinement continued until no further improvement of the
1Rfree was observed. At this point, electron density maps showed
Bclear density for several solvent molecules, sulfate ions (two in the
cS433A and R619M mutants, one in R619E and R619Y mutants),
rand glycerol molecules (R619M and S433A mutants), and these
4were added to the model. Iterative steps of positional and atomic
B factor refinement followed by manual rebuilding were performed B
Auntil no further improvement of R factors was achieved. Simulated
annealing omit maps were calculated to validate the correctness of m
(the structure in the area of the mutations. In all cases, the models
had good stereochemistry, as determined by using the program 2ROCHEK (Laskowski et al., 1993), with all amino acids lying in
he most favorable or allowed regions on the Ramachandran plot.
efinement statistics are shown in Table 1.
pectrophotometric Characterization
f ArnA Dehydrogenase Mutants
he standard reaction mixture contained 25 mM Tris (pH 8.0), 5 mM
-mercapto ethanol, 0.2 mg/ml BSA, 10% glycerol, 100 mM KCl, 3
M NAD+, and 1 mM (or 5 mM) UDP-glucuronic acid. The reaction
as started with the addition of 200 nM wild-type and 1 M mutant
rnA dehydrogenase. Enzyme activity was measured by following
he increase of absorbance due to the produced NADH at 340 nm
or 20 min. All enzyme assays were carried out at 37°C in a final
olume of 800 l.
upplemental Data
upplemental Data including a movie highlighting the conforma-
ional changes occurring in ArnA_DH upon substrate binding are
vailable at http://www.structure.org/cgi/content/full/13/6/929/DC1.
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